Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Pandemic Means Another Delay For Canadian Pricing Reforms

Executive Summary

Industry has have welcomed another delay to the implementation of drug pricing reforms that aim to lower Canadian drugs prices.

You may also be interested in...



COVID-19 Causes Further Delay To Canada’s Controversial Pricing Reforms

A delay to implementing drug pricing reforms is an opportunity for Canadian authorities to come up with better proposals, say industry representatives, while authorities remain adamant that action is necessary to lower prices.

Canadian Drug Pricing Reforms Could Lead To Medicine Shortages

Drug pricing reform in Canada could prompt companies to launch elsewhere or see drugs diverted to the US.

European Parliament Signs Off Regulation To Tackle Medicine Shortages

The legislation will establish a new EU platform for monitoring and reporting medicines shortages.

Topics

UsernamePublicRestriction

Register

PS145496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel